Nexalin Technology CEO sends letter to shareholders

Nexalin Technology (NXL) providing an update on the Company’s technology advancements, clinical achievements, and strategic focus for 2025. “Recently, Dr. David Owens, our Chief Medical Officer, and I conducted a comprehensive review of our clinical programs and strategic initiatives for 2025… Over the past 24 months, Nexalin has either initiated, completed, or is actively conducting 29 Institutional Review Board)-approved clinical trials. These studies have consistently demonstrated the potential of our 15 mA waveform to safely and effectively treat a range of mental health disorders… Strategic Focus for 2025… Primary Mood Disorders: Expanding research and trials targeting insomnia, depression, and migraines. Military and Government Relations: Strengthening partnerships to address TBI and PTSD within military and veteran populations. Alzheimer’s and Addiction: Accelerating research in these areas, leveraging pilot studies and publications that demonstrate DIFS’ potential. European Market Expansion: In 2025, we are actively pursuing CE Mark approval for our Gen-3 Halo device to enable entry into the European market. This critical step will align with our global strategy of making Nexalin technology available to more patients worldwide…. In addition to our U.S.-based achievements, Nexalin has received regulatory approvals in China, Brazil, and Oman, paving the way for global adoption of DIFS technology.”